These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25243894

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L, Lee LB, Pang J, Plise EG, Zhang X.
    Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
    [Abstract] [Full Text] [Related]

  • 5. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B.
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [Abstract] [Full Text] [Related]

  • 6. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

  • 7. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 8. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF.
    Cancer Res; 2009 Jul 15; 69(14):5885-92. PubMed ID: 19567673
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
    Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE.
    Drug Metab Dispos; 2009 Feb 15; 37(2):439-42. PubMed ID: 19056914
    [Abstract] [Full Text] [Related]

  • 12. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 15; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 13. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH.
    Cancer Res; 2005 Apr 01; 65(7):2577-82. PubMed ID: 15805252
    [Abstract] [Full Text] [Related]

  • 14. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
    Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.
    Pharm Res; 2007 Sep 01; 24(9):1720-8. PubMed ID: 17380257
    [Abstract] [Full Text] [Related]

  • 15. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.
    J Neurochem; 2007 Sep 01; 102(6):1749-1757. PubMed ID: 17696988
    [Abstract] [Full Text] [Related]

  • 16. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S, Sane R, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2011 Jan 01; 336(1):223-33. PubMed ID: 20952483
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J, Gavrilova O, Petzinger E.
    J Vet Pharmacol Ther; 2009 Feb 01; 32(1):87-96. PubMed ID: 19161460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.